Company Overview and News

43
Closing Bell: Sensex up over 300 pts, midcaps underperform; IT zooms, ONGC dips

2018-05-25 moneycontrol
Benchmark indices rose, driven by IT stocks, such as, Infosys and TCS on the back of a weak rupee. The IT index has gained 18 percent so far this year. The rupee has weakened by more than 7 percent so far this year, as surging crude oil prices weigh on India, the world’s third-largest importer, raising fears that soaring costs could drive up inflation and widen the trade deficit.
500325 JIPKY MS.PRE MS.PRF 531548 MS.PRG MS.PRA 534976 533207 AJANTPHARM BJJQY MS 500570 RLNIY AXB 524804 JETAIRWAYS 531335 AXBA BAJFINANCE MS.PRI FORTIS MS.PRK SOMANYCERA AUROPHARMA RELIANCE 532617 533155 BHRQY JUBLFOOD 532215 AXISBANK RIGD JBLWY BHARTIARTL 505324 TATAMOTORS MANUGRAPH 500034 IBN JPASSOCIAT 532843 AXBKY 532532 532454 VMART ICICIBANK 532331 JPINFRATEC 532174 ARBQY ZYDUSWELL TTM

0
Manugraph India board approves merger scheme

2018-05-08 thehindubusinessline
The board of Manugraph India on Tuesday considered and approved a scheme of merger. The scheme entails absorption of Constrad Agencies (Bombay) Pvt Ltd, and Maiu Enterprises and Santsu Finance and Investment Pvt Ltd with Manugraph India. The scheme is subject to sanction from the National Company Law Tribunal, approvals from the stock exchanges, SEBI, the respective shareholders and creditors of the amalgamating and amalgamated companies and such other statutory or regulatory approvals, the company said in a notice to the stock exchanges.
505324 MANUGRAPH

0
Manugraph India Limited - Outcome of Board Meeting

2018-05-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
505324 MANUGRAPH

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...